Elisabeth Buchdunger
- Hematology top 0.02%
- Molecular Biology top 1%
- Genetics top 0.05%
- Oncology top 0.5%
- Rheumatology top 0.1%
- Co-authors
- Brian DrukerNicholas LydonJ. ZimmermannRenaud CapdevilleSayuri Ohno-JonesShu TamuraGerald M. SegalDebra Resta
- Topics
- Chronic Myeloid Leukemia Treatments (33 papers)Chronic Lymphocytic Leukemia Research (20 papers)HER2/EGFR in Cancer Research (18 papers)
- Cited by
- HematologyGeneticsRheumatology
- Partner nations
- SwitzerlandUnited StatesFinland
In The Last Decade
Elisabeth Buchdunger
60 papers receiving 16.8k citations
Hit Papers
Peers
Comparison fields: 5 of 139
- Hematology 8.7k
- Molecular Biology 5.7k
- Genetics 5.6k
- Oncology 4.4k
- Rheumatology 3.9k
Countries citing papers authored by Elisabeth Buchdunger
This map shows the geographic impact of Elisabeth Buchdunger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisabeth Buchdunger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisabeth Buchdunger more than expected).
Fields of papers citing papers by Elisabeth Buchdunger
This network shows the impact of papers produced by Elisabeth Buchdunger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisabeth Buchdunger. The network helps show where Elisabeth Buchdunger may publish in the future.
Co-authorship network of co-authors of Elisabeth Buchdunger
This figure shows the co-authorship network connecting the top 25 collaborators of Elisabeth Buchdunger. A scholar is included among the top collaborators of Elisabeth Buchdunger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisabeth Buchdunger. Elisabeth Buchdunger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 11 | |
| 2 | 224 | |
| 3 | 29 | |
| 4 | 24 | |
| 5 | 214 | |
| 6 | 201 | |
| 7 | Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lympoblastic leukemia with the philadelphia chromosome | 9 |
| 8 | 6 | |
| 9 | 72 | |
| 10 | Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemiabreakdown → | 3811 |
| 11 | 265 | |
| 12 | 40 | |
| 13 | 44 | |
| 14 | 7 | |
| 15 | 34 | |
| 16 | 122 | |
| 17 | 288 | |
| 18 | 37 | |
| 19 | 27 | |
| 20 | 74 |
About Elisabeth Buchdunger
Elisabeth Buchdunger is a scholar working on Hematology, Genetics and Oncology, having authored 60 papers that have together received 17.4k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (33 papers), Chronic Lymphocytic Leukemia Research (20 papers) and HER2/EGFR in Cancer Research (18 papers). The work is most often cited by research in Hematology (8.7k citations), Genetics (5.6k citations) and Rheumatology (3.9k citations). Elisabeth Buchdunger has collaborated with scholars based in Switzerland, United States and Finland. Frequent co-authors include Brian Druker, Nicholas Lydon, J. Zimmermann, Renaud Capdeville, Sayuri Ohno-Jones, Shu Tamura, Gerald M. Segal, Debra Resta, Moshe Talpaz and J. Ford. Their work appears in journals such as New England Journal of Medicine, Journal of Biological Chemistry and Circulation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.